Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study Silvio Danese,1 Séverine Vermeire,2 Wen Zhou,3 Aileen Pangan,3 Jesse Siffledeen,4 Xavier Hébuterne,5 Hiroshi Nakase,6 Peter D.R. Higgins,7 Min-Hu Chen,8 Yuri Sanchez Gonzalez,3 Bidan Huang,3 Wangang Xie,3 John Liu,3 Michael A. Weinreich,3 Remo Panaccione9 Confidential Do not use externally | Company Confidential © 2019 1Humanitas University and Humanitas Research Hospital, IRCCS, Milan, Italy; 2Department of Gastroenterology & Hepatology, University Hospital Leuven, KU Leuven, Leuven, Belgium; 3AbbVie Inc., North Chicago, IL, USA; 4University of Alberta, Edmonton, Canada; 5Université Côte d’Azur, CHU de Nice, Nice, France; 6Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan; 7Department of Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA; 8Division of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 9Division of Gastroenterology, University of Calgary, Calgary, Alberta American College of Gastroenterology (ACG), October 22-27, 2021, Hybrid Conference P19